A multicenter, randomized trial evaluating 30-day and 6-month clinical outcomes with three different treatment strategies (coronary angioplasty + abciximab, intracoronary stent + abciximab, and intracoronary stent + placebo) in patients undergoing percutaneous coronary intervention.
Phase of Trial: Phase III
Latest Information Update: 27 Apr 2010
At a glance
- Drugs Abciximab (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Embolism and thrombosis
- Focus Therapeutic Use
- Sponsors Centocor
- 25 Nov 2006 New trial record.